One emerging industry could be the next investment opportunity
Global biotech company Zoono Group Limited (ASX:ZNO) Founder and CEO Paul Hyslop is an expert on long lasting antimicrobial protection and outlines the industry opportunity to The Capital Network’s Executive Director Lelde Smits. Long lasting antimicrobial protection is an emerging industry and Mr Hyslop outlines why it presents a compelling investment opportunity, why global product developers have not embraced it, and where the future lies for the industry.
Lelde Smits: Hello, I’m Lelde Smits for The Capital Network, and joining me is the founder, CEO and major shareholder of New Zealand-based, ASX listed Zoono Group (ASX:ZNO), Paul Hyslop. Paul, welcome.
Paul Hyslop: Hi, Lelde. Thank you. Nice to be here.
Lelde Smits: Paul is an expert on long lasting antimicrobial solutions and Paul I’d like to start by asking you what exactly are they and why are we only now just starting to hear about long lasting antimicrobial solutions?
Paul Hyslop: A long lasting antimicrobial solution is a product that is applied to surfaces, skin, fabrics, and it will kill all the bacteria on the surfaces applied to, and then it will afford protection for extended periods of time.
Lelde Smits: Where has this technology originated from and how is it now being developed?
Paul Hyslop: It actually originated a long time ago. The active ingredient was originally developed way, way back. But it wasn’t really used. I found the active ingredient about ten years ago, and I saw a lot of different applications for it. It was quite an unstable active ingredient, quite hard to work with, and we’ve evolved the active ingredient to a commercial product.
Lelde Smits: When we look at the global market for long lasting antimicrobial solutions, why aren’t we seeing global players really implement more of this technology into the products that we see on supermarket shelves?
Paul Hyslop: Global players in the pharmaceutical and chemical industry, their business model is to sell millions of litres of product over and over again that are applied many times a day, many times a week, many times a year. And those millions of litres, they end up in the waterways, they end up in the ocean, they end up in the ground. They often do not break down in the environment, but for them to go into a long lasting antimicrobial solution is totally against their philosophy.
Lelde Smits: When you look at the outlook for this sort of technology, that you have described as disruptive to the industry, where do you see the biggest opportunities being presented in terms of geographies and also sectors that are applying long lasting antimicrobial solutions?
Paul Hyslop: It can be used globally of course and the sectors are almost endless, from cruise liners to aircrafts, to hospitals, to age care facilities, childcare facilities, food manufacturing facilities, farms, poultry farms for instance, pig farms. It’s almost endless, really, it goes on and on, households, universities, schools.
Lelde Smits: That certainly is quite a list. Thank you so much for outlining all of the opportunities for this emerging sector.
Paul Hyslop: Great, thank you.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.